6-thio-inosine | 574-25-4

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-thio-inosine
• 英文别名: 9-[(2R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purine-6-thione
• CAS: 574-25-4；892-49-9；4334-79-6；4988-64-1；7687-43-6；10173-26-9；15639-75-5；22746-58-3；26188-04-5；28069-17-2；122557-20-4
• 化学式: C₁₀H₁₂N₄O₄S
• 分子量: 284.296
• InChiKey: NKGPJODWTZCHGF-DGPXGRDGSA-N

物化性质

• 熔点：
  220-223 °C(lit.)
• 密度：
  1.4599 (rough estimate)
• 溶解度：
  可溶于水基（轻微）、DMSO（轻微）、甲醇（非常轻微，加热）
• 沸点：
  714.7±70.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  144
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 危险性防范说明：
  P264,P501,P301+P312+P330,P270
• 危险性描述：
  H302

制备方法与用途

概述

脱氧核苷是由碱基（如嘌呤或嘧啶）与核糖或脱氧核糖结合形成的糖基胺。其中，核糖是环状戊糖；而脱氧核糖则没有羟基。常见的实例包括胞苷、尿苷、腺苷、鸟苷、胸苷和肌苷。核苷类似物广泛用作抗病毒剂和抗癌剂，因为它们能够在RNA或DNA合成过程中充当反转录酶抑制剂或链终止剂。

此外，核苷磷酸化酶是一种在哺乳动物细胞和细菌中广泛分布的转移酶，在核苷代谢补救途径中起着关键作用。这类酶具有双重功能：一方面，在无机磷酸盐的存在下催化糖苷键的可逆切割，以生成碱基和相应的-1-磷酸；另一方面，它们促进嘌呤或嘧啶碱基与核苷之间的戊糖转移反应，即转糖基反应。

6-疏基嘌呤核苷是一种特殊的核苷形式。

生物活性

6-Thioinosine (6TI) 是一种抗代谢物的嘌呤衍生物，具有抑制脂肪生成的作用。它可以降低PPAR γ、C/EBPα及其靶基因如LPL（脂蛋白脂肪酶）、CD36、aP2和LXRα mRNA 的表达水平。

文献信息

• Anti-HCV nucleoside derivatives
  申请人：——

  公开号：US20030008841A1

  公开（公告）日：2003-01-09

  The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

  本发明涉及新颖和已知的嘌呤和嘧啶核苷衍生物，已发现这些衍生物对丙型肝炎病毒（HCV）具有活性。本发明声明利用这些衍生物治疗HCV感染，以及本文所披露的新颖核苷衍生物。
• Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
  申请人：Gilead Pharmasset LLC

  公开号：US10100076B2

  公开（公告）日：2018-10-16

  The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  所述的发明是关于一种用于在宿主中（包括动物，特别是人类）使用一般式（I）-（XXIII）的核苷或其药用可接受的盐或前药，对Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括流感A和B）或Paramyxoviridae（包括RSV）感染，或与异常细胞增殖相关的疾病进行座位的组合物和方法。该发明还提供了一种有效的过程，用于使用实时聚合酶链反应（“RT-PCR”）在宿主中定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量。此外，该发明还揭示了可以与样本中存在的病毒量成比例发出荧光的探针分子。
• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• [EN] NOVEL N-ALKOXYADENINE DERIVATIVES ACTING AS CYTOKINE INHIBITORS<br/>[FR] NOUVEAUX DERIVES DE N-ALCOXYADENINE INHIBANT LA CYTOKINE
  申请人：NOVO NORDISK A/S

  公开号：WO1998001459A1

  公开（公告）日：1998-01-15

  (EN) The present invention relates to novel $i(N),9-disubstituted adenine derivatives and novel aristeromycin analogues which are further substituted at the adenine 2-position, and which have a hydroxymethyl group, or an ester or ester isostere at a position corresponding to the ribose 4-position, and pharmaceutically acceptable addition salts thereof. The compounds act as cytokine inhibitors. Also covered are processes for preparation of the above derivatives and their pharmaceutical compositions as well as methods for using the compounds and compositions as drugs for the treatment of disorders involving cytokines in humans.(FR) L'invention concerne des nouveaux dérivés d'adénine $i(N),9-disubstitués et de nouveaux analogues d'aristéromycine substitués en outre à la position 2 de l'adénine, et ayant un groupe hydroxyméthyle ou un ester ou un ester isostère à une position qui correspond à la position 4 de la ribose, et les sels d'addition pharmaceutiquement acceptable de ces substances. De tels composés inhibent la cytokine. On décrit des procédés relatifs à l'élaboration des dérivés et de leurs compositions pharmaceutiques ainsi que des procédés relatifs à l'utilisation des composés et des compositions comme médicaments pour traiter les affections impliquant la cytokine chez l'homme.

  本发明涉及新型$i(N),9-二取代腺嘌呤衍生物和新型阿里斯特霉素类似物，后者在腺嘌呤2位进一步取代，并在相应于核糖4位的位置具有羟甲基基团、酯或酯类似物，以及其药学上可接受的加合物盐。这些化合物作为细胞因子抑制剂。还涵盖了制备上述衍生物及其药物组成物的过程，以及将这些化合物和组合物作为治疗人类细胞因子相关疾病的药物的方法。
• Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation
  申请人：Stuyver Lieven

  公开号：US20110269707A1

  公开（公告）日：2011-11-03

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用通式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了探针分子，可以与样品中存在的病毒数量成比例地发出荧光。